Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Table 1
Baseline characteristics.
Patient demographics
HVD (n = 352, 54.3%)
LVD (n = 296, 45.7%)
value
Age, median, year (IQR)
75 (68–80)
74 (68–80)
0.2242
M stage, n (%)
<0.0001
1A
0
72 (24.3%)
1B
268 (76.1%)
224 (75.7%)
1C
84 (23.9%)
0
Gleason grade group, n (%)
0.0013
1
0
8 (3.3%)
2
6 (2.1%)
12 (4.9%)
3
26 (9.1%)
34 (13.9%)
4
64 (22.3%)
47 (19%)
5
191 (66.5%)
145 (58.9%)
Initial PSA level, ng/ml, median (IQR)
511.5 (181.25–1234.47)
98.2 (45–256.6)
<0.0001
Hb, g/dL, median (IQR)
11.5 (9.7–13.2)
12.7 (11.6–13.9)
<0.0001
Ca, g/dL, median (IQR)
8.7 (8.2–9.1)
8.8 (8.3–9.1)
0.9528
ALP, U/L, median (IQR)
146 (94–324)
74 (60–101)
<0.0001
CRPC, n (%)
<0.0001
Yes
232 (65.9%)
143 (48.3%)
No
120 (34.1%)
153 (51.7%)
PSA kinetics after ADT
TTN, month, median (IQR)
7.15 (3.7–13.3)
11.9 (6.25–20.9)
<0.0001
Nadir PSA level, ng/ml, median (IQR)
2.2 (0.23–17.18)
0.23 (0.02–1.7)
0.0015
PSARR, %/month, median (IQR)
12.5 (6.8–22.04)
7.99 (4.38–14.9)
0.0002
TFNTC, month, median (IQR)
3.25 (2.5–7.9)
8.3 (2.7–26.1)
<0.0001
PSADT, month, median (IQR)
2.3 (1.4–4.15)
3.6 (1.9–7)
<0.0001
CRPC: castration-resistant prostate cancer, TTN: time to PSA nadir, PSARR: PSA reduction rate, TFNTC: time from PSA nadir to CRPC, and PSADT: PSA doubling time.
